PKI
Get informed when a big investor buys or sells
+ FollowUndervalued by 4.3% based on the discounted cash flow analysis.
| Market cap | $14.46 Billion |
|---|---|
| Enterprise Value | $16.95 Billion |
| Dividend Yield | $0.28 (0.27%) |
| Earnings per Share | $2.07 |
| Beta | 1.1 |
| Outstanding Shares | 111,876,000 |
| P/E Ratio | 48.54 |
|---|---|
| PEG | -1349.77 |
| Price to Sales | 4.61 |
| Price to Book Ratio | 1.8 |
| Enterprise Value to Revenue | 5.84 |
| Enterprise Value to EBIT | 46.97 |
| Enterprise Value to Net Income | 70 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.47 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0425▼ 421.94% |
|---|---|
| Total Calls | 209,500▲ 1147.02% |
| Total Puts | 8,900▼ 87.57% |
Holdings and activity of institutional investors.
| Ownership % | 94.53%▼ 3.10% |
|---|---|
| Total Invested | $10.36B▲ 2.80% |
| Investors Holding | 519▼ 12.00% |
No data
This committee provides the technical analysis and 'scoring' for all tax legislation, directly influencing corporate tax structures, capital investment incentives, and the overall tax burden that impacts Revvity's financial planning and investment decisions.
As the primary committee for taxation and trade, it directly impacts Revvity's profitability through corporate tax policy, R&D credits, and trade tariffs on imported components or exported instruments, significantly affecting corporate valuations and operations.
This committee controls discretionary federal spending, directly allocating funds for scientific research, defense programs, and health initiatives. These allocations provide direct revenue streams and R&D opportunities for Revvity's products within government labs and research institutions.
This committee regulates the FDA and NIH. FDA approvals and NIH research funding directly drive demand and R&D activities in the pharmaceutical and biotech sectors, Revvity's primary customer industries. Labor laws also impact manufacturing costs.
This committee oversees the Department of Defense. DoD laboratories engage in extensive R&D (e.g., materials science, chemical/biological analysis) requiring advanced analytical instruments, making DoD a direct potential customer and source of R&D funding for Revvity.
With its broad jurisdiction over science and interstate commerce, this committee promotes scientific research and development initiatives, which directly increases the market for Revvity's laboratory instruments. It also oversees agencies relevant to technology and innovation.
This committee oversees the Department of Energy, whose national labs are significant users of analytical instrumentation for research. It also impacts the oil and gas and mining sectors, where Revvity's instruments are crucial for analysis and quality control.
This committee regulates the EPA, which sets environmental standards. These standards often require precise analytical testing, directly driving demand for Revvity's environmental monitoring instruments and solutions within regulated industries.